Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study

Abstract

Sitagliptin use was not associated with an excess risk of all cause hospital admission or death compared with other glucose lowering agents among newly treated patients with type 2 diabetes. Most patients prescribed sitagliptin in this cohort were concordant with clinical practice guidelines, in that it was used as add-on treatment.